Ausgabe 5/2012
Inhalt (32 Artikel)
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies
G. S. Falchook, M. Duvic, D. S. Hong, J. Wheler, A. Naing, J. Lim, R. Kurzrock
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures
Takeshi Takahara, Hiroyuki Nitta, Yasushi Hasegawa, Naoko Itou, Masahiro Takahashi, Satoshi Nishizuka, Go Wakabayashi
Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection
Jian-Feng Lu, Erik Rasmussen, Beth Y. Karlan, Ignace B. Vergote, Lynn Navale, Mita Kuchimanchi, Rebeca Melara, Daniel E. Stepan, David M. Weinreich, Yu-Nien Sun
Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial
M. J. McKeage, P. C. Fong, X. Hong, J. Flarakos, J. Mangold, Y. Du, C. Tanaka, H. Schran
Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia
Mikkel Krogh-Madsen, Brendan Bender, Morten Krogh Jensen, Ove Juul Nielsen, Lena E. Friberg, Per Hartvig Honoré
Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma
Ho-Jin Shin, Joo Seop Chung, Moo-Kon Song, Seon-Kyeong Kim, Sangmin Choe, Goon-Jae Cho
Inhibition of Csn3 expression induces growth arrest and apoptosis of hepatocellular carcinoma cells
Yong-sheng Yu, Zheng-hao Tang, Qing-chun Pan, Xiao-hua Chen, Xue-ni Liu, Guo-qing Zang
Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002)
Masashi Kanai, Etsuro Hatano, Syogo Kobayashi, Yutaka Fujiwara, Daisuke Sakai, Yuzo Kodama, Tetsuo Ajiki, Hiroaki Nagano, Tatsuya Ioka
The effect of aprepitant and race on the pharmacokinetics of cyclophosphamide in breast cancer patients
Christine M. Walko, Austin J. Combest, Ivan Spasojevic, Angela Y. C. Yu, Shriya Bhushan, J. Heyward Hull, Janelle Hoskins, Delma Armstrong, Lisa Carey, Frances Collicio, E. Claire Dees
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study)
Masato Ozaka, Yuji Matsumura, Hiroshi Ishii, Yasushi Omuro, Takao Itoi, Hisatsugu Mouri, Keiji Hanada, Yasutoshi Kimura, Iruru Maetani, Yoshinobu Okabe, Masaji Tani, Takaaki Ikeda, Susumu Hijioka, Ryouhei Watanabe, Shinya Ohoka, Yuki Hirose, Masafumi Suyama, Naoto Egawa, Atsushi Sofuni, Takaaki Ikari, Toshifusa Nakajima
Correlation between low-level expression of the tumor suppressor gene TAp73 and the chemoresistance of human glioma stem cells
Xiaogang Hu, Nan Wu, Peiyuan Xia, Sicang Yu, Fengjun Sun, Jianhong Chen
The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials
Ye-min Wang, Bao-zhe Jin, Fang Ai, Chang-hong Duan, Yi-zhong Lu, Ting-fang Dong, Qing-lin Fu
Prospective evaluation of the drug-metabolizing enzyme polymorphisms and toxicity profile of docetaxel in Korean patients with operable lymph node-positive breast cancer receiving adjuvant chemotherapy
Kyu-pyo Kim, Jin-Hee Ahn, Sung-Bae Kim, Kyung Hae Jung, Dok Hyun Yoon, Jung Shin Lee, Sei-Hyun Ahn
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
Sandhya Girish, Manish Gupta, Bei Wang, Dan Lu, Ian E. Krop, Charles L. Vogel, Howard A. Burris III, Patricia M. LoRusso, Joo-Hee Yi, Ola Saad, Barbara Tong, Yu-Waye Chu, Scott Holden, Amita Joshi
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
Takashi Kobayashi, Tomonobu Koizumi, Toshihide Agatsuma, Masanori Yasuo, Kenji Tsushima, Keishi Kubo, Seiichiro Eda, Hiroshi Kuraishi, Shigeru Koyama, Tsutomu Hachiya, Nariaki Ohura
The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus
Mark Stroh, John Palcza, Jacqueline McCrea, Sabrina Marsilio, Sheila Breidinger, Deborah Panebianco, Amy Johnson-Levonas, Walter K. Kraft, Keith Orford, Gail Murphy, Nancy Agrawal, Michele Trucksis, John A. Wagner, Marian Iwamoto
Midostaurin does not prolong cardiac repolarization defined in a thorough electrocardiogram trial in healthy volunteers
Adam del Corral, Catherine Dutreix, Alice Huntsman-Labed, Sebastien Lorenzo, Joel Morganroth, Robert Harrell, Yanfeng Wang
Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials
Yong Yu, Xun Xu, Ziyan Du, Minhua Shi
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer
Guo Bing Zhang, Jian Chen, Lin Run Wang, Jun Li, Ming Wei Li, Nong Xu, Yang Wang, Jian Zhong Shentu
Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations
V. Ludovini, F. Bianconi, L. Pistola, V. Minotti, R. Chiari, R. Colella, G. Bellezza, F. R. Tofanetti, A. Siggillino, E. Baldelli, A. Flacco, D. Giuffrida, A. Sidoni, L. Crinò
Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats
Izet M. Kapetanovic, Miguel Muzzio, David L. McCormick, Thomas N. Thompson, William D. Johnson, Thomas L. Horn, Altaf Mohammed, Chinthalapally V. Rao, Levy Kopelovich
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Thea Eline Hetland, Janne Kærn, Martina Skrede, Berit Sandstad, Claes Tropé, Ben Davidson, Vivi Ann Flørenes
Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer
Ningning Dong, Mingyu Wang, Huiqing Li, Yongchun Cui, Qisen Guo
Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice
Jian-hua Gong, Xiu-jun Liu, Yi Li, Yong-su Zhen
Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer
Duk Joo Lee, Tae Sung Sohn, Do Hoon Lim, Hee Kyung Ahn, Se Hoon Park, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Dong Il Choi, Kyoung Mee Kim, Min Gew Choi, Jae Hyung Noh, Jae Moon Bae, Sung Kim, Byung Hoon Min, Won Ki Kang
A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer
Daniel J. Renouf, Stephen Welch, Malcolm J. Moore, Monika K. Krzyzanowska, Jennifer Knox, Ronald Feld, Geoffrey Liu, Helen MacKay, Jennifer Petronis, Lisa Wang, Eric Chen
A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer
N. Karachaliou, Ch. Kouroussis, P. Papakotoulas, K. Kalbakis, K. Tryfonidis, N. Vardakis, E. Poppis, V. Georgoulias, D. Mavroudis
Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment
Yoichi Ozawa, Kazutomi Kusano, Takashi Owa, Akira Yokoi, Makoto Asada, Kentaro Yoshimatsu
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers
Che Lin, Dar-Ren Chen, King-Jen Chang, Tsai-Wang Chang, Hwei-Chung Wang
Analysis of the pharmacodynamic activity of the mTOR inhibitor ridaforolimus (AP23573, MK-8669) in a phase 1 clinical trial
Lori Berk, Monica M. Mita, Jeff Kreisberg, Camille L. Bedrosian, Anthony W. Tolcher, Tim Clackson, Victor M. Rivera
Phase I and pharmacologic study of weekly amrubicin in patients with refractory or relapsed lung cancer: Central Japan Lung Study Group (CJLSG) 0601 trial
Chiyoe Kitagawa, Hideo Saka, Shigehisa Kajikawa, Kouki Mori, Masahide Oki, Ryujiro Suzuki
Prognostic significance of MRP5 immunohistochemical expression in glioblastoma
George A. Alexiou, Anna Goussia, Spyridon Voulgaris, Andreas D. Fotopoulos, George Fotakopoulos, Antigoni Ntoulia, Anastasia Zikou, Perikles Tsekeris, Maria I. Argyropoulou, Athanasios P. Kyritsis